A carregar...
Phase I Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma
BACKGROUND: Antiangiogenic therapies for malignant gliomas often result in transient response, and recurrent disease is characterized by adoption of invasive and hypoxic phenotype. The notch signaling pathway is activated in gliomas, and augments cell migration and hypoxic response. Here we report a...
Na minha lista:
| Publicado no: | J Neurooncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5571739/ https://ncbi.nlm.nih.gov/pubmed/27826680 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-016-2263-1 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|